CD274 and neoplasm: These therapies work by neutralizing CTLA4 or through blocking the interaction between PD-L1 (CD274), expressed on tumor epithelia and surrounding supportive cells, and PD-1, expressed on infiltrating CD8+ cytotoxic T-cells, a process that is regulated by MHC class I and the components of the neoantigen presentation apparatus.